10.1182/blood-2017-05-785659 - Phase 1 clinical trial using mbIL21 e...

This document has been corrected

Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation

10.1182/blood-2017-05-785659

Published Online: 2017-10-19

Journal: Blood•Publisher: American Society of Hematology

Authors: Alison Gulbis•Cecele J. Denman•Dana Willis•Dean A. Lee•Doris Soebbing•Elizabeth J. Shpall•Gabriela Rondon•Indreshpal Kaur•Jolie R. Schafer•Julianne Chen•Kai Cao•Katayoun Rezvani•Richard E. Champlin•Roland Bassett•Sairah Ahmed•Stefan O. Ciurea

This document has been corrected

Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation

10.1182/blood-2017-05-785659

Published Online: 2017-10-19

Journal: Blood

NOW

2018-12-27•Erratum

Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017;130(16):1857-1868.

10.1182/blood-2018-11-884247

* information provided by CrossRef

2018-12-27•Erratum

10.1182/blood-2018-11-884247

* information provided by CrossRef

2017-10-19•Published

2018-12-27•Erratum

Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017;130(16):1857-1868.

10.1182/blood-2018-11-884247

* information provided by CrossRef

This document has been corrected

Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation

10.1182/blood-2017-05-785659

Published Online: 2017-10-19

Journal: Blood•Publisher: American Society of Hematology